• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Lyra Therapeutics, Inc. - Common Stock (NQ:LYRA)

    2.250 -0.090 (-3.85%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 21, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Lyra Therapeutics, Inc. - Common Stock

    News headline image
    Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis
    From Lyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Lyra Therapeutics and LianBio Announce Strategic Partnership and Exclusive License Agreement to Develop and Commercialize LYR-210 in Greater China and Other Asian Markets
    From Lyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Lyra Therapeutics to Present at the William Blair 41st Annual Growth Stock Conference
    From Lyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Lyra Therapeutics To Present At The Jefferies Virtual Healthcare Conference
    From Lyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Lyra Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
    From Lyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Lyra Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
    From Lyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Lyra Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update
    From Lyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual
    From Lyra Therapeutics, Inc.
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.